CeriBell (NASDAQ:CBLL) CTO Sells $206,238.72 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the completion of the transaction, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at $3,097,886.72. This trade represents a 6.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Woo also recently made the following trade(s):

• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The stock was sold at an average price of $18.25, for a total transaction of $147,587.75.
• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $13,951.95.

CeriBell Price Performance

Shares of CBLL stock remained flat at $18.57 during trading hours on Friday. The company’s stock had a trading volume of 217,757 shares, compared to its average volume of 301,845. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The company’s fifty day moving average is $19.39 and its 200 day moving average is $17.37. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $698.97 million, a P/E ratio of -12.63 and a beta of 0.94.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. Sell-side analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Several institutional investors and hedge funds have recently added to or reduced their stakes in CBLL. Russell Investments Group Ltd. raised its stake in CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after buying an additional 854 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period. Deutsche Bank AG grew its holdings in CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares in the last quarter. Finally, Royal Bank of Canada increased its position in shares of CeriBell by 10.8% during the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after purchasing an additional 1,514 shares during the last quarter.

Analysts Set New Price Targets

CBLL has been the subject of several research analyst reports. Canaccord Genuity Group raised their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.